{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:24:20Z","timestamp":1794029060196,"version":"4.8.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"18","license":[{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,24]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Although intensive induction chemotherapy (IC) remains the standard of care for younger patients with acute myeloid leukemia (AML), hypomethylating agents\u00a0+ venetoclax (HMA\/VEN) can lead to durable remission among older patients with nucleophosmin 1 (NPM1) mutations. Whether IC or HMA\/VEN is superior in patients aged \u226560 years with NPM1-mutant AML is unknown. We performed an international, multicenter retrospective cohort study of 221 patients (147 IC and 74 HMA\/VEN) with previously untreated NPM1-mutant AML. Composite complete remission (cCR) (defined as CR\u00a0+ CR with incomplete count recovery) rate was similar for IC and HMA\/VEN (cCR, 85% vs 74%; P\u00a0=\u00a0.067). Although overall survival (OS) was favorable with IC in unselected patients compared with HMA\/VEN (24-month OS, 59% [95% confidence interval (CI), 52-69%] vs 38% [95%\u00a0CI, 27-55%]; P\u00a0=\u00a0.013), it was not statistically different among patients aged 60-75 years (60% [95%\u00a0CI, 52-70%] vs 44% [95%\u00a0CI, 29-66%]; P\u00a0=\u00a0.069) and patients who received an allogeneic stem cell transplant (70% [95%\u00a0CI, 58-85%] vs 66% [95%\u00a0CI, 44-100%]; P\u00a0=\u00a0.56). Subgroup analyses suggested that patients with normal cytogenetics (24-month OS, 65% [95%\u00a0CI, 56-74%] with IC vs 40% [95%\u00a0CI, 26-60%] with HMA\/VEN; P\u00a0=\u00a0.009) and without FLT3 internal tandem duplication mutations might benefit from IC compared with HMA\/VEN (24-month OS, 68% [95%\u00a0CI, 59-79%] vs 43% [95%\u00a0CI, 29-63%]; P\u00a0=\u00a0.008). In multivariable analysis, OS was not statistically different between patients treated with IC and HMA\/VEN (hazard ratio for death with HMA\/VEN vs IC, 0.71; 95%\u00a0CI, 0.40-1.27; P\u00a0=\u00a0.25).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024012858","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T18:59:47Z","timestamp":1719601187000},"page":"4845-4855","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["Intensive induction chemotherapy vs hypomethylating agents in\u00a0combination with venetoclax in <i>NPM1<\/i>-mutant AML"],"prefix":"10.1182","volume":"8","author":[{"given":"Jan Philipp","family":"Bewersdorf","sequence":"first","affiliation":[{"name":"1Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7245-9652","authenticated-orcid":false,"given":"Shai","family":"Shimony","sequence":"additional","affiliation":[{"name":"2Division of Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8542-2944","authenticated-orcid":false,"given":"Rory M.","family":"Shallis","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine, Section of Hematology, Yale University and Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Liu","sequence":"additional","affiliation":[{"name":"4Department of Data Science, Dana Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8810-7117","authenticated-orcid":false,"given":"Guillaume","family":"Berton","sequence":"additional","affiliation":[{"name":"5D\u00e9partement d'h\u00e9matologie, Institut Paoli-Calmettes, Universit\u00e9 d'Aix-Marseille, INSERM U1068, CNRS, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva J.","family":"Schaefer","sequence":"additional","affiliation":[{"name":"2Division of Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"6Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine, Section of Hematology, Yale University and Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2892-2643","authenticated-orcid":false,"given":"Aaron D.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan M.","family":"Stein","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Marcucci","sequence":"additional","affiliation":[{"name":"7Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4407-4389","authenticated-orcid":false,"given":"Rebecca P.","family":"Bystrom","sequence":"additional","affiliation":[{"name":"2Division of Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9822-806X","authenticated-orcid":false,"given":"R. Coleman","family":"Lindsley","sequence":"additional","affiliation":[{"name":"2Division of Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9218-215X","authenticated-orcid":false,"given":"Evan C.","family":"Chen","sequence":"additional","affiliation":[{"name":"2Division of Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Ramos Perez","sequence":"additional","affiliation":[{"name":"7Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Stein","sequence":"additional","affiliation":[{"name":"7Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Pullarkat","sequence":"additional","affiliation":[{"name":"7Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Aldoss","sequence":"additional","affiliation":[{"name":"7Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7865-2306","authenticated-orcid":false,"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[{"name":"2Division of Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna S.","family":"Neuberg","sequence":"additional","affiliation":[{"name":"4Department of Data Science, Dana Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Stone","sequence":"additional","affiliation":[{"name":"2Division of Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Garciaz","sequence":"additional","affiliation":[{"name":"5D\u00e9partement d'h\u00e9matologie, Institut Paoli-Calmettes, Universit\u00e9 d'Aix-Marseille, INSERM U1068, CNRS, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8625-7023","authenticated-orcid":false,"given":"Brian","family":"Ball","sequence":"additional","affiliation":[{"name":"7Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Stahl","sequence":"additional","affiliation":[{"name":"2Division of Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"issue":"9","key":"2024092412005994000_bib1","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/ajh.26989","article-title":"NPM1-mutated acute myeloid leukemia: new pathogenetic and therapeutic insights and open questions","volume":"98","author":"Falini","year":"2023","journal-title":"Am J Hematol"},{"issue":"10","key":"2024092412005994000_bib2","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/s41375-022-01666-2","article-title":"Current status and future perspectives in targeted therapy of NPM1-mutated AML","volume":"36","author":"Ranieri","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"2024092412005994000_bib3","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2024092412005994000_bib4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"10388","key":"2024092412005994000_bib5","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"2024092412005994000_bib6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2024092412005994000_bib7","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2024092412005994000_bib8","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/bloodadvances.2019001267","article-title":"Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens","volume":"4","author":"Lachowiez","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"2024092412005994000_bib9","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajh.26061","article-title":"Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: a propensity score matched analysis stratified by risk of treatment-related mortality","volume":"96","author":"Maiti","year":"2021","journal-title":"Am J Hematol"},{"issue":"29","key":"2024092412005994000_bib10","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1200\/JCO.19.00416","article-title":"Chromosomal abnormalities and prognosis in NPM1-mutated acute myeloid leukemia: a pooled analysis of individual patient data from nine international cohorts","volume":"37","author":"Angenendt","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"2024092412005994000_bib11","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa074306","article-title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia","volume":"358","author":"Schlenk","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"2024092412005994000_bib14","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood-2012-06-431122","article-title":"Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy","volume":"121","author":"Pratcorona","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2024092412005994000_bib15","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1182\/blood-2007-08-109090","article-title":"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia","volume":"111","author":"Gale","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2024092412005994000_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41408-021-00410-w","article-title":"Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia","volume":"11","author":"Maiti","year":"2021","journal-title":"Blood Cancer J"},{"issue":"11","key":"2024092412005994000_bib17","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1038\/s41375-023-02016-6","article-title":"Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European LeukemiaNet risk classification","volume":"37","author":"Eckardt","year":"2023","journal-title":"Leukemia"},{"issue":"5","key":"2024092412005994000_bib18","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/bloodadvances.2023011173","article-title":"Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML","volume":"8","author":"Chan","year":"2024","journal-title":"Blood Adv"},{"issue":"5","key":"2024092412005994000_bib19","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024092412005994000_bib20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ajh.26757","article-title":"Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia","volume":"98","author":"Stahl","year":"2023","journal-title":"Am J Hematol"},{"issue":"9","key":"2024092412005994000_bib21","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jama.2023.1363","article-title":"DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant","volume":"329","author":"Dillon","year":"2023","journal-title":"JAMA"},{"issue":"4","key":"2024092412005994000_bib22","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood.2023021579","article-title":"Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"18","key":"2024092412005994000_bib23","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1200\/JCO.23.01599","article-title":"Targeting molecular measurable residual disease and low-blast relapse in AML with venetoclax and low-dose cytarabine: a prospective phase II study (VALDAC)","volume":"42","author":"Tiong","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"2024092412005994000_bib24","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/bjh.16722","article-title":"Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia","volume":"192","author":"Tiong","year":"2021","journal-title":"Br J Haematol"},{"key":"2024092412005994000_bib25","doi-asserted-by":"crossref","first-page":"100806","DOI":"10.1016\/j.blre.2021.100806","article-title":"The complete story of less than complete responses: the evolution and application of acute myeloid leukemia clinical responses","volume":"48","author":"Shallis","year":"2021","journal-title":"Blood Rev"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/18\/4845\/2243762\/blooda_adv-2024-012858-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/18\/4845\/2243762\/blooda_adv-2024-012858-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T13:39:20Z","timestamp":1727185160000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/18\/4845\/516799\/Intensive-induction-chemotherapy-vs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":23,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024,9,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024012858","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]}}}